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Abstract
Growth of benign tumours and tumour-like lesions of bone results in osteolysis which may cause pathological fracture.
Bisphosphonates are anti-osteolytic agents which have proved effective in the treatment of number of osteolytic conditions.
In this study we report the results of treatment with the aminobisphosphonate, pamidronate, of three benign osteolytic
tumours of bone, two cases of fibrous dysplasia and one of Langerhans cell histiocytosis. In all three cases there was clinical
and radiological improvement following treatment. Radiologically, bone lesions did not exhibit progressive enlargement.
Two cases of fibrous dysplasia also showed features suggestive of increased bone formation. These findings indicate that
bisphosphonates are likely to be useful in controlling the osteolysis of benign tumours/tumour-like lesions of bone,
particularly in those cases where surgical intervention is not possible or multifocal lesions are present.
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Introduction
The growth of benign tumours and tumour-like
lesions of bone is associated with osteolysis. This
occurs ata variable rat e and may resultin bone
weakness and pathological fracture. Actively growing
benign tumours which are confined within the bone
cause expansion and deformity (Stage II lesions) and
some (Stage III lesions) are locally aggressive and
cause considerable bone destruction.
1 Treatment
of enlarging bone tumours is essentially surgical (i.e.,
excision of the lesion). Complete excision is, how-
ever, notalways possible and as a consequence t he
lesion may recur, resulting in progressive bone
destruction.
A number of recent studies have reported the use
of anti-osteolytic agents such as bisphosphonates to
inhibit the progressive osteolysis associated with the
growth of benign bone tumours.
2,3 In this paper, we
reportour experience in using t he aminobisphos-
phonate, pamidronate, to treat three large osteolytic
benign tumours (two cases of fibrous dysplasia and
one of Langerhans cell histiocytosis) in which surgery
was not indicated. Two of these cases had extensive
multifocal disease. The results of this treatment
were assessed in terms of clinical and radiological
evidence of progressive bone destruction and com-
pared with those of previous studies which have used
bisphosphonates to treat these lesions.
Case reports
Case 1 –Monostotic fibrous dysplasia
RC, a 29-year-old housewife presented with debili-
tating left forearm pain. Fibrous dysplasia was
diagnosed at the age of 17 years after multiple
pathological fractures involving her left proximal
radius. Curettage and grafting of the lesion at this
time provided tissue for histological confirmation of
the diagnosis of fibrous dysplasia (Fig. 1a). The
autologous bone graft was subsequently resorbed
(Fig. 1b). She remained symptom-free for 9 years
but then developed increasing pain of the left
proximal radius over a 12-month period. A bone
scan showed modest radionucleotide uptake in a
solitary tumour of the radius. Examination of radio-
graphs showed an increase in size of the lesion over
12 years. MRI identified an expansile lytic lesion of
the left proximal radius with soft tissue involvement.
Features were consistent with the diagnosis of
fibrous dysplasia.
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(30mg/day for 3 days) at 4-month intervals. She
had mild intolerance to pamidronate (chest tight-
ness) after the first dose but this was treated
symptomatically and she suffered no further side
effects. The bisphosphonate therapy made a signifi-
cant difference to her pain; the pain score, which
was 6/10 before treatment, fell to 0/10 after the
first cycle and she remained asymptomatic for 2
months after the completion of the third cycle. The
serum alkaline phosphatase and urinary hydro-
xyproline were normal throughout treatment.
Compared with pre-treatment radiographs, radio-
graphic evidence of infilling of the bone lesion was
noted 6 months after commencing pamidronate
therapy (Fig. 2).
Case 2 –Polyostotic fibrous dysplasia
KM, a 37-year-old female housekeeper, presented at
the age of 33 years with a 2-year history of right groin
and knee pain. Prior to her orthopaedic assessment,
she had a full gynaecological and general surgical
assessmentfor her groin pain including surgical
exploration to exclude a femoral hernia and pelvic/
soft tissue malignancy. Past medical history included
fracture of the right tibia at the age of 10 years and
re-fracture of the tibia 10 months later. A radiologi-
cal diagnosis of fibrous dysplasia was made att hat
time and no further investigations or treatment were
undertaken. Skeletal survey confirmed the diagnosis
of polyostotic fibrous dysplasia affecting the right
hemi-pelvis, rightproximal and dist al femur, right
tibia and talus and first ray of the foot. There
was no associated endocrinopathy or musculoskele-
tal abnormality. Radiographs showed extensive
bone lysis of the right proximal femur; there was
associated cortical thinning and evidence of an
incipient fracture. A trucut bone biopsy of the right
proximal femur confirmed the diagnosis of fibrous
dysplasia and excluded bone malignancy. MRI of
her brain (for persistent headaches) was normal.
The patient had intramedullary nailing (AO/ASIF
unreamed IMN) of the right femur for her impend-
ing fracture.
The patient noticed significant improvement
of her clinical symptoms immediately after surgery,
but 5 months later became symptomatic again
Fig. 1. (a) AP radiograph of the solitary lytic lesion of fibrous dysplasia in the left proximal radius after bone grafting. (b) AP
radiograph of the lesion showing resorption of the bone graft following surgery.
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at rest and on standing. She was then started on
a pamidronate treatment protocol: 30mg/day for 3
days at 3-month intervals. After the first cycle, she
had a florid reaction to pamidronate with increas-
ing pain over a 2-week period. This responded to
non-steroidal anti-inflammatory treatment. After
the second infusion, she experienced some transient
flu-like symptoms. She received a total of eight
courses of pamidronate. The pain scores before the
initiation of treatment were as follows: right groin
4/10; righthip 6/10; rightankle 6/10. Att he lat est
follow-up, 6 months after the completion of pami-
dronate, she has no groin or hip pain but continues
to have right ankle and mid-foot pain; the latter is
most likely secondary to degenerative arthritis of
the ankle joint and an associated tibialis posterior
tendinopathy. Her pain scores and function have
significantly improved with only occasional discom-
fort, whilst sitting (due to the pelvic lesion). Urine
hydroxyproline and serum alkaline phosphatase
levels, both of which were elevated, normalised
after treatment with pamidronate and have remained
normal. In plain radiographs of the femur the
lesion has shown progressive remodelling over the
24-month follow-up period with thickening of
the surrounding cortex, resolution of the lytic
lesion including some infilling of the expanded
bone (Figs. 3 and 4).
Case 3 –Multifocal Langerhans Cell Histiocytosis
WG, a 33-year-old female clerical worker, presented
at the age of 31 years with a 7-month history of left
hip pain which was presentatnightand worse on
standing. Clinical examination was unremarkable
apartfrom pain and limit ed range of movementof
the left hip. Past medical history included partial
thyroidectomy for thyrotoxicosis and antidepressant
treatment.
Radiographs of her pelvis at presentation showed
multifocal aggressive lytic lesions of the left aceta-
bulum and the right inferior pubic ramus (Fig. 5).
Skeletal survey (including bone scan and MRI)
identified a non-painful lytic lesion of the proximal
femur and skull. The MRI showed that these lesions
were associated with a soft tissue mass. A CT-guided
biopsy of the pelvic tumour was inconclusive and
an open incisional biopsy of the left pelvic lesion
confirmed the diagnosis of Langerhans cell histio-
cytosis. Following frozen section histological con-
formation of the diagnosis, she had an intra-operative
injection of steroids into the cavity of the left pelvic
lesion. She then commenced systemic prednisolone
treatment (20–40mg daily reducing over 6 months).
There was modest symptomatic improvement
(in pain relief and the ability to weight bear) for the
first 3 months, but after 6 months little clinical or
radiological improvement was noted. Steroid therapy
Fig. 2. Radiographic evidence of infilling of the bone lesion following treatment with pamidronate.
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(similar to that used for case 2), was started. The
patient had two cycles of i.v. pamidronate (three
daily doses of 30, 60 and 60mg) with intervals of
2 and 5 months. Initially, in the first 6 weeks of
pamidronate treatment, she had a dramatic clinical
response, the pain score decreasing from 9/10
to 4/10. The pain later returned and modest
clinical benefit was noted after the second cycle.
Radiologically, although there was little infilling of
the large lytic acetabular lesion, the smaller bone
lesions showed progressive resolution (Fig. 6). No
side effects were noted following pamidronate
treatment apart from some initial exacerbation of
her bone pain and flu-like symptoms during the
second cycle; these were thought to be due to too
rapid intravenous administration of pamidronate.
Serum alkaline phosphatase remained normal
throughout the treatment. Further investigations for
diabetes insipidus and pituitary gland function, MRI
and CT scan of the pelvis, MRI of the brain were
normal. A CT scan of her chestshowed nodular
pulmonary LCH.
Discussion
Actively growing benign tumours and tumour-like
lesions of bone are associated with increased bone
resorption which weakens the integrity of the
skeleton. Complete surgical removal or extirpation
of these lesions is not always possible and control of
the progressive osteolysis and bone weakness that is
caused by the growth of these lesions is a significant
clinical problem. Bisphosphonate treatment is well-
established in controlling bone destruction due to
metastatic disease, Paget’s disease, osteoporosis and
multiple myeloma.
4,5 In this study, we have shown
that in three patients, one with monostotic fibrous
dysplasia, one with polyostotic fibrous dysplasia and
one with multifocal Langerhans cell histiocytosis,
treatment with an aminobisphosphonate resulted
in inhibition and control of the progressive bone
destruction associated with active enlargement of
these lesions.
Fibrous dysplasia is a relatively common benign
bone lesion which is usually monostotic but in about
20% of cases is polyostotic. Clinically, most patients
present with bone pain due to enlargement of the
bone lesion. Spontaneous healing of these lesions
Fig. 3. AP radiograph of the right femur showing a large
lesion of fibrous dysplasia with a subtrochanteric pathological
fracture. The lesion has been stabilised with an unreamed
intramedullary nail.
Fig. 4. AP radiograph of the right femur 14 months after
surgery and after the patient was commenced on pamidronate
therapy.
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towards pain relief and surgical correction of
deformity and pathological fractures.
6,7 Surgical
treatment options include various modes of internal
fixation and/or bone grafting; this is aimed at
providing mechanical supportand biomechanical
realignment of the affected bones. However, bone
graft (as in Case 1 in this study) is characteristically
resorbed as the lesion continues to enlarge. The
two cases of fibrous dysplasia which received
pamidronate treatment in the present study showed
clinical and radiological improvement. Both cases
showed some resolution of symptoms including an
improvementin t he pain score. There was also
radiological evidence of bone formation and infilling
of the lytic lesion. Liens et al.
8 also noted a significant
decrease in bone pain in nine patients with sympto-
matic and severe fibrous dysplasia who were treated
with pamidronate and followed-up for a period of
4 years. Some radiological resolution of the osteolytic
Fig. 5. Multifocal lytic pelvic lesions of Langerhans cell histiocytosis in the left acetabulum and the right inferior pubic ramus.
Fig. 6. Ten months after pamidronate treatment radiological evidence of progressive resolution of bone lysis is seen in the lesion in the
right inferior pubic ramus.
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study. A further report by Chapurlat et al.
2 on
pamidronate treatment of 20 patients with mono-
stotic and polyostotic fibrous dysplasia also noted
significantclinical and radiological improvement
of the lesions at an average follow-up of 39 months.
The severity of bone pain and the number of painful
sites was reduced significantly. Some infilling of
osteolytic areas was noted on radiographs in nine of
the 20 patients following treatment. All biochemical
markers of bone remodelling were lowered signifi-
cantly. More recently, Lane et al.
3 reported findings
in six cases of fibrous dysplasia treated with either
oral alendronate or intravenous pamidronate and
oral alendronate. They reported significant clinical
improvement, with an average decrease in the
pain score of 75% for the patients who received
alendronate and pamidronate at 2 years follow-up.
There was also an improvement in the bone quality
with four of the six patients showing progressive
ossification of the lesion and a decrease in the
diameter of the lesions. All the patients who received
combination intravenous and oral therapy had a
significantdecrease in collagen breakdown product s
(urinary N-telopeptide) as compared with the
patients who only received oral agents.
Clinical and radiological improvementwas also
noted following pamidronate treatment of a case of
multifocal Langerhans cell histiocytosis (LCH) in
the present study. Although the clinical improvement
was short-lived, no enlargement of the largest
bone lesion was noted and several small volume
lesions actually showed progressive radiographic
resolution. Langerhans cell proliferation in LCH
may produce single or multiple lesion in skeletal
tissues.
7 Treatment options for specifically painful
and/or radiologically aggressive lesions include cur-
ettage, intralesional infiltration of corticosteroids,
chemotherapy and radiation therapy. There are
two previous reports of administration of bisphos-
phonates to patients with LCH. Elomaa et al.
9
treated two adults with multi-focal LCH with oral
clodronate for 6 months and noted pain relief with
evidence of regression of the bone lesions and
decreased bone resorption after approximately 1
month of treatment. More recently, Farran et al.
10
reported the results of bisphosphonate treatment in a
14-year-old boy with multifocal LCH resistant to
chemotherapy, steroids, non-steroidal anti-inflam-
matory drugs for NSAID and narcotic analgesics.
The patient responded well to two cycles of i.v.
pamidronate and remained pain-free 4 months after
his last treatment cycle. An MRI confirmed regres-
sion of some of the lesions. The LCH patient in our
study showed significant pain relief 6 weeks after
initiation of treatment with i.v. pamidronate but this
improvementwas notmaint ained. Radiographs
taken 1 month after the completion of the second
cycle showed some evidence of resolution of the large
lytic acetabular lesion. (The patient has declined
further investigation, limiting our analysis for study-
ing progression of the lesion following treatment).
The rationale for using bisphosphonates to control
the osteolysis associated with the growth of benign
tumours in bone is that these compounds inhibit
osteoclastic resorption and increased bone turnover
without affecting osteoblast function.
5,11,12 Bisphos-
phonates are chemically stable analogues of inor-
ganic pyrophosphate and have a high affinity for
bone mineral.
5,13 This tissue-specific targeting of
Table 1. Clinical details of bisphosphonate-treated cases
Sex/age Duration of
treatment with
bisphosphonates
Biochemical
markers*
Follow-up
duration
Clinical resultRadiological
result
Case 1:
Monostotic
fibrous
dysplasia
29-year-old/
Female
3-cycles
at4-mont h
intervals
Normal
throughout
treatment
18 months Pain score
decreased from
6/10 to 0/10;
remains
asymptomatic
Progressive
infilling of radial
lytic lesion
Case 2:
Polyostotic
fibrous
dysplasia
37-year-old/
Female
8-cycles at
3-month
intervals
Normal
throughout
treatment
24 months Pain score
decreased from
6/10 to 0/10;
remains
asymptomatic
in 2 out
of 3 lesions
Progressive
infilling and
remodelling of
femoral lytic
lesion
Case 3:
Multifocal
LCH
33-year-old/
Female
2-cycles at
2- and 5-month
intervals
Normal
throughout
treatment
18 months Pain score
decreased
from 9/10
to 4/10
Progressive
resolution of
smaller lesions;
minimal infilling
of large acetabular
lesion
*Alkaline phosphatase and urinary hydroxyproline.
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of osteoclast activity, is extremely useful in control-
ling the growth of bone lesions. Tumour osteolysis
is mediated by osteoclasts and bisphosphonates are
found in high concentration beneath osteoclasts at
sites of bone resorption (where bone mineral is most
exposed) rather than at sites of bone formation.
Bisphosphonates inhibit osteoclast-mediated bone
resorption in several ways.
5,13 Binding of bisphos-
phonates to hydroxyapatite results in changes in
the physico-chemical structure of hydroxyapatite
crystals. Bisphosphonates also inhibit osteoclast
bone-resorbing activity and decrease osteoclast
formation from mononuclear phagocyte precur-
sors;
14,15 they also increase apoptosis in osteoclasts
with consequent loss of attachment to bone.
16
Bisphosphonates do not inhibit bone formation.
5,11
They do not significantly influence the formation of
callus in fracture repair and in general increase the
mechanical strength of bone following fracture.
12 As
skeletal growth is also not greatly affected, bisphos-
phonates are thus likely to prove useful agents in the
treatment of bone osteolysis associated with bone
tumours, many of which arise in the immature
skeleton of young patients.
Bisphosphonates are also recognised to have an
analgesic effectin bone t umours
5,13 such as LCH
where cells within the lesion are known to produce
cytokines and prostaglandins which can stimulate
progressive osteoclast resorption and pain.
14,15 The
analgesic effectof bisphosphonat es is explained on
the basis that active osteoclasts produce prostaglan-
dins and interleukins that mediate pain (even in the
absence of bone damage) and pamidronate, in
addition to being a direct osteoclast inhibitor, is
known to decrease the production of cytokines
including interleukin-1, interleukin-6 and tumour
necrosis factor .
5,17
In summary, bisphosphonates proved effective in
controlling tumour osteolysis and in reducing the
pain in two cases of fibrous dysplasia and one of
multifocal LCH. A similar rationale has been used
for employing other anti-osteolytic agents such as
calcitonin to control pathological bone resorption
associated with the growth of giant cell granulomas
of the jaw.
18,19 The role of bisphosphonates in
tumour management would appear to merit further
investigation.
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